Clinical and Molecular Hepatology (대한간학회지)

The Korean Association for the Study of the Liver (대한간학회)
권호 표지
DOI QR코드

DOI QR Code

Overview and recent trends of systematic reviews and meta-analyses in hepatology

  • Kim, Gaeun (Department of Nursing, Keimyung University College of Nursing) ;
  • Baik, Soon Koo (Department of Internal Medicine, Yonsei University Wonju College of Medicine)
  • Received : 2014.05.14
  • Accepted : 2014.05.29
  • Published : 2014.06.25
⟨ Previous Next ⟩

Abstract

A systematic review (SR) is a research methodology that involves a comprehensive search for and analysis of relevant studies on a specific topic. A strict and objective research process is conducted that comprises a systematic and comprehensive literature search in accordance with predetermined inclusion/exclusion criteria, and an assessment of the risk of bias of the selected literature. SRs require a multidisciplinary approach that necessitates cooperation with clinical experts, methodologists, other experts, and statisticians. A meta-analysis (MA) is a statistical method of quantitatively synthesizing data, where possible, from the primary literature selected for the SR. Review articles differ from SRs in that they lack a systematic methodology such as a literature search, selection of studies according to strict criteria, assessment of risk bias, and synthesis of the study results. The importance of evidence-based medicine (EBM) in the decision-making for public policy has recently been increasing thanks to the realization that it should be based on scientific research data. SRs and MAs are essential for EBM strategy and evidence-based clinical practice guidelines. This review addresses the current trends in SRs and MAs in the field of hepatology via a search of recently published articles in the Cochrane Library and Ovid-MEDLINE.

Keywords

References

  1. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. updated March 2011. handbook web site, < http://handbook.cochrane.org/>. Accessed 2014.
  2. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions : explanation and elaboration. J Clin Epidemiol 2009;62:e1-e34. https://doi.org/10.1016/j.jclinepi.2009.06.006
  3. Shea BJ, Grimshaw JM, Wells G, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR : A measurement tool to assess the methodological quality of systematic review. BMC med res methodol 2007;7:10. https://doi.org/10.1186/1471-2288-7-10
  4. Liu H, Wang X, Wan G, Yang Z, Zeng H. Telbivudine versus entecavir for nucleos(t)ide-naive HBeAg-positive chronic hepatitis B: a meta-analysis. Am J Med Sci 2014;347:131-138. https://doi.org/10.1097/MAJ.0b013e318286878d
  5. Jiang H, Wang J, Zhao W. Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and metaanalysis. Eur J Clin Microbiol Infect Dis 2013;32:11-18. https://doi.org/10.1007/s10096-012-1723-6
  6. Yu W, Zhao C, Shen C, Wang Y, Lu H, Fan J. The efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and metaanalysis. PLoS One 2013;8:e65952. https://doi.org/10.1371/journal.pone.0065952
  7. Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, et al. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLoS One 2013;8:e68152. https://doi.org/10.1371/journal.pone.0068152
  8. He B, Zhang Y, Lu MH, Cao YL, Fan YH, Deng JQ, et al. Glucocorticoids can increase the survival rate of patients with severe viral hepatitis B: a meta-analysis. Eur J Gastroenterol Hepatol 2013;25:926-934. https://doi.org/10.1097/MEG.0b013e32835f4cbd
  9. Xu H, Zeng T, Liu JY, Lei Y, Zhong S, ShengYJ, et al. Measures to reduce mother-to-child transmission of Hepatitis B virus in China: a meta-analysis. Dig Dis Sci 2013;59:242-258.
  10. Liu MH, Sheng YJ, Liu JY, Hu HD, Zhang QF, Ren H. Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis. Ann Saudi Med 2013;33:169-176
  11. Schonberger K, Riedel C, Ruckinger S, Mansmann U, Jilg W, Kries-RV. Determinants of long-term protection after hepatitis B vaccination in infancy: a meta-analysis. Pediatr Infect Dis J 2013;32:307-313. https://doi.org/10.1097/INF.0b013e31827bd1b0
  12. Huang R, Hao Y, Fan Y, Yang C, Wu K, Cao S, et al. Association between cytotoxic T-lymphocyte-associated antigen 4 +49A/G polymorphism and persistent hepatitis B virus infection in the Asian population: evidence from the current studies. Genet Test Mol Biomarkers 2013;17:601-606. https://doi.org/10.1089/gtmb.2013.0069
  13. Xia Y, Luo H, Liu JP, Gluud C. Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection. Cochrane Database Syst Rev 2013;4:CD009004.
  14. Wei F, Liu SK, Liu XY, Li ZJ, Li B, Zhou YL, et al. Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B. Eur J Clin Microbiol Infect Dis 2013;32:657-669. https://doi.org/10.1007/s10096-012-1789-1
  15. The Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. KASL web site, . Accessed 2014.
  16. Hauser G, Awad T, Brok J, Thorlund K, Stimac D, Mabrouk M, et al. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. Cochrane Database Syst Rev 2014;2:CD005441.
  17. Druyts E, Thorlund K, Wu P, Kanters S, Yaya S, Cooper CL, et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis 2013;56:961-967. https://doi.org/10.1093/cid/cis1031
  18. Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, et al. Pegylated interferon-${\alpha}2a$ and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis. Drugs 2013;73:263-277. https://doi.org/10.1007/s40265-013-0027-1
  19. Zhu Q, Li N, Han Q, Zhang P, Yang C, Zeng X, et al. Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis. Antiviral Res 2013;98:373-379. https://doi.org/10.1016/j.antiviral.2013.04.009
  20. Kieran J, Schmitz S, O'Leary A, Walsh C, Bergin C, Norris S, et al. The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. Clin Infect Dis 2013;56:228-235. https://doi.org/10.1093/cid/cis880
  21. Goralczyk AD, Cameron S, Amanzada A. Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and-experienced patients. BMC Gastroenterol 2013;13:148. https://doi.org/10.1186/1471-230X-13-148
  22. Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med 2013;158:114-123. https://doi.org/10.7326/0003-4819-158-2-201301150-00576
  23. Rabie R, Mumtaz K, Penner EL. Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: a systematic review and meta-analysis. Liver Transpl 2013;19:36-48. https://doi.org/10.1002/lt.23516
  24. Koretz RL, Pleguezuelo M, Arvaniti V, Barrera Baena P, Ciria R, Gurusamy KS, et al. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database Syst Rev 2013;1:CD003617.
  25. Nikolova K, Gluud C, Grevstad B, Jakobsen JC. Nitazoxanide for chronic hepatitis C. Cochrane Database Syst Rev 2014;4:CD009182.
  26. Villar LM, Del Campo JA, Ranchal I, Lampe E, Romero-Gomez M. Association between vitamin D and hepatitis C virus infection: A meta-analysis. World J Gastroenterol 2013;19:5917-5924. https://doi.org/10.3748/wjg.v19.i35.5917
  27. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342. https://doi.org/10.1002/hep.26141
  28. Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta‐analysis. Hepatology 2013;58:1215-1224. https://doi.org/10.1002/hep.26387
  29. Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, LaarMv. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis 2013;13:181. https://doi.org/10.1186/1471-2334-13-181
  30. Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC infect dis 2013;13:288. https://doi.org/10.1186/1471-2334-13-288
  31. Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther 2013;37:921-936. https://doi.org/10.1111/apt.12300
  32. Abozaid SM, Shoukri M, Al-Qahtani A, Al-Ahdala MN. Prevailing genotypes of hepatitis C virus in Saudi Arabia: a systematic analysis of evidence. Ann Saudi Med 2013;33:1-5.
  33. Bota S, Sporea I, Sirli R, Neghina AM, Popescu A, Strain M. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis. Clin Drug Investig 2013;33:325-331. https://doi.org/10.1007/s40261-013-0074-0
  34. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013;57(Suppl 2):S80-S89. https://doi.org/10.1093/cid/cit306
  35. Liu J, Yu W, Liu S. Positive ratio of specific antibodies to F protein in serum samples from chronic HCV-infected patients using an enzyme-linked immunosorbent assay: systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2013;25:1152-1158.
  36. Sublette VA, Douglas MW, McCaffery K, George J, Perry KN. Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic review. Liver Int 2013;33:894-903. https://doi.org/10.1111/liv.12138
  37. Lieveld FI, van Vlerken LG, Siersema PD, Van Erpecum KJ. Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review. Ann Hepatol 2013;12:380-391.
  38. Shah HA, Abu-Amara M. Education provides significant benefits to patients with hepatitis B virus or hepatitis C virus infection: a systematic review. Clin Gastroenterol Hepatol 2013;11:922-933. https://doi.org/10.1016/j.cgh.2013.04.024
  39. Nair Kesavachandran C, Haamann F, Nienhaus A. Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One 2013;8:e55364. https://doi.org/10.1371/journal.pone.0055364
  40. Davies A, Singh KP, Shubber Z, Mills EJ, Cooke G, Ford N. Treatment Outcomes of Treatment-Naïve Hepatitis C Patients co-infected with HIV: a systematic review and meta-analysis of observational cohorts. PLoS One 2013;8:e55373. https://doi.org/10.1371/journal.pone.0055373
  41. Raza A, Mittal S, Sood GK. Interferon‐associated retinopathy during the treatment of chronic hepatitis C: a systematic review. J Viral Hepat 2013;20:593-599. https://doi.org/10.1111/jvh.12135
  42. Van-Lume DS, Albuquerque Mde F, Souza AI, Domingues AL, Lopes EP, Morais CN, et al. Association between Schistosomiasis mansoni and hepatitis C: systematic review. Rev Saude Publica 2013;47:414-24. https://doi.org/10.1590/S0034-910.2013047004247
  43. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2013;56:806-816. https://doi.org/10.1093/cid/cis1007
  44. Cottrell EB, Chou R, Wasson N, Rahman B, Guise JM. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013;158:109-113. https://doi.org/10.7326/0003-4819-158-2-201301150-00575
  45. Ingsathit A, Kamanamool N, Thakkinstian A, Sumethkul V. Survival advantage of kidney transplantation over dialysis in patients with hepatitis C: a systematic review and meta-analysis. Transplantation 2013;95:943-948. https://doi.org/10.1097/TP.0b013e3182848de2
  46. Chou R, Cottrell EB, Wasson N, Rahman B, Guise JM. Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013;158:101-108. https://doi.org/10.7326/0003-4819-158-2-201301150-00574
  47. Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2013;12:CD008623.
  48. Xiang Z, Chen YP, Ma KF, Ye YF, Zheng L, Yang YD, et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol 2013;13:140. https://doi.org/10.1186/1471-230X-13-140
  49. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2013;19:6911-6918. https://doi.org/10.3748/wjg.v19.i40.6911
  50. Parker R, Armstrong MJ, Corbett C, Rowe IA, Houlihan DD. Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment pharmacol Ther 2013;37:845-854. https://doi.org/10.1111/apt.12279
  51. Liu ZL, Xie LZ, Zhu J, Li GQ, Grant SJ, Liu JP. Herbal medicines for fatty liver diseases. Cochrane Database Syst Rev 2013;8:CD009059.
  52. Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev 2013;14:417-431. https://doi.org/10.1111/obr.12020
  53. Chu MJ, Hickey AJ, Phillips AR, Bartlett AS. The impact of hepatic steatosis on hepatic ischemia-reperfusion injury in experimental studies: a systematic review. Biomed Res Int 2013;2013:192029.
  54. Shi KQ, Fan YC, Pan ZZ, Lin XF, Liu WY, Chen YP, et al. Transient elastography: a meta‐analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver Int 2013;33:62-71. https://doi.org/10.1111/liv.12003
  55. Bota S, Herkner H, Sporea I, Salzl P, Sirli R, Neghina AM, et al. Meta‐analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. Liver Int 2013;33:1138-1147. https://doi.org/10.1111/liv.12240
  56. Abd El Rihim AY, Omar RF, Fathalah W, El Attar I, Hafez HA, Ibrahim W. Role of fibroscan and APRI in detection of liver fibrosis: a systematic review and meta-analysis. Arab J Gastroenterol 2013;14:44-50. https://doi.org/10.1016/j.ajg.2013.05.002
  57. Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. World J Gastroenterol 2013;19:6665-6678. https://doi.org/10.3748/wjg.v19.i39.6665
  58. Chen XD, He FQ, Yang L, Yu YY, Zhou ZG. Laparoscopic splenectomy with or without devascularization of the stomach for liver cirrhosis and portal hypertension: a systematic review. ANZ J Surg 2013;83:122-128. https://doi.org/10.1111/ans.12003
  59. Junker AE, Als-Nielsen B, Gluud C, Gluud LL. Dopamine agents for hepatic encephalopathy. Cochrane Database Syst Rev 2014;2:CD003047.
  60. Chavez-Tapia NC, Cesar-Arce A, Barrientos-Gutierrez T, Villegas-Lopez FA, Mendez-Sanchez N, Uribe M. A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy. Nutr J 2013;12:74. https://doi.org/10.1186/1475-2891-12-74
  61. Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, et al. Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr 2013;143:1263-1268. https://doi.org/10.3945/jn.113.174375
  62. Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA. A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mortality. Liver Int 2013;33:40-52. https://doi.org/10.1111/j.1478-3231.2012.02790.x
  63. Mota VG, Markman Filho B. Echocardiography in chronic liver disease: systematic review. Arq Bras Cardiol 2013;100:376-385.
  64. Yu S, Jianqin H, Wei W, Jianrong H, Yida Y, Jifang S, et al. The efficacy and safety of nucleos(t)ide analogues in the treatment of HBVrelated acute-on-chronic liver failure: a meta-analysis. Ann Hepatol 2013;12:364-372.
  65. Friedrich-Rust M, Klopffleisch T, Nierhoff J, Herrmann E, Vermehren J, Schneider MD, et al. Contrast‐Enhanced Ultrasound for the differentiation of benign and malignant focal liver lesions: a metaanalysis. Liver Int 2013;33:739-755. https://doi.org/10.1111/liv.12115
  66. Wu LM, Xu JR, Lu Q, Hua J, Chen J, Hu J. A pooled analysis of diffusion-weighted imaging in the diagnosis of hepatocellular carcinoma in chronic liver diseases. J Gastroenterology Hepatol 2013;28:227-234. https://doi.org/10.1111/jgh.12054
  67. Rodríguez-Perálvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol 2013;20:325-339. https://doi.org/10.1245/s10434-012-2513-1
  68. Zhao ZH, Fan YC, Yang Y, Wang K. Association between Ras association domain family 1A promoter methylation and hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 2013;19:7189-7196. https://doi.org/10.3748/wjg.v19.i41.7189
  69. Gao P, Jiao SC, Bai L, Wang H, Jing FF, Yang JL. Detection of circulating tumour cells in gastric and hepatocellular carcinoma: a systematic review. J Int Med Res 2013;41:923-933. https://doi.org/10.1177/0300060513489789
  70. Xu Y, Li L, Xiang X, Wang H, Cai W, Xie J, et al. Three common functional polymorphisms in microRNA encoding genes in the susceptibility to hepatocellular carcinoma: a systematic review and meta-analysis. Gene 2013;527:584-593. https://doi.org/10.1016/j.gene.2013.05.085
  71. Weis S, Franke A, Mössner J, Jakobsen JC, Schoppmeyer K. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev 2013;12:CD003046.
  72. Cucchetti A, Piscaglia F, Cescon M, Ercolani G, Pinna AD. Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol 2013;19:4106-4118. https://doi.org/10.3748/wjg.v19.i26.4106
  73. Duan C, Liu M, Zhang Z, Ma K, Bie P. Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and metaanalysis. World J Surg Oncol 2013;11:190. https://doi.org/10.1186/1477-7819-11-190
  74. Lin NC, Nitta H, Wakabayashi G. Laparoscopic major hepatectomy: a systematic literature review and comparison of 3 techniques. Ann Surg 2013;257:205-213. https://doi.org/10.1097/SLA.0b013e31827da7fe
  75. Rao AM, Ahmed I. Laparotscopic versus open liver resection for benign and malignant hepatic lesions in adults. Cochrane Database Syst Rev 2013;5:CD010162.
  76. Yin Z, Liu C, Chen Y, Bai Y, Shang C, Yin R, et al. Timing of hepatectomy in resectable synchronous colorectal liver metastases (SCRLM): Simultaneous or delayed? Hepatology 2013;57:2346-2357. https://doi.org/10.1002/hep.26283
  77. Ho CM, Wakabayashi G, Nitta H, Ito N, Hasegawa Y, Takahara T. Systematic review of robotic liver resection. Surg Endosc 2013;27:732-739. https://doi.org/10.1007/s00464-012-2547-2
  78. Aubin JM, Rekman J, Vandenbroucke-Menu F, Lapointe R, Fairfull-Smith RJ, Mimeault R, et al. Systematic review and meta‐analysis of liver resection for metastatic melanoma. Br J Surg 2013;100:1138-1147. https://doi.org/10.1002/bjs.9189
  79. Taefi A, Abrishami A, Nasseri-Moghaddam S, Eghtesad B, Sherman M. Surgical resection versus liver transplant for patients with hepatocellular carcinoma. Cochrane Database Syst Rev 2013;6:CD006935.
  80. Chan DL, Morris DL, Chua TC. Clinical efficacy and predictors of outcomes of repeat hepatectomy for recurrent hepatocellular carcinoma - a systematic review. SurgOncol 2013;22:e23-e30.
  81. Coolsen MM, Wong-Lun-Hing EM, van Dam RM, van der Wilt AA, Slim K, Lassen K, et al. A systematic review of outcomes in patients undergoing liver surgery in an enhanced recovery after surgery pathways. HPB (Oxford) 2013;15:245-251.
  82. Grant RC, Sandhu L, Dixon PR, Greig PD, Grant DR, McGilvray ID. Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta‐analysis. Clin Transplant 2013;27:140-147. https://doi.org/10.1111/ctr.12031
  83. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-337. https://doi.org/10.7326/0003-4819-158-5-201303050-00005
  84. Gu L, Liu H, Fan L, Lv Y, Cui Z, Luo Y, et al. Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2014;140:199-210. https://doi.org/10.1007/s00432-013-1528-8
  85. Abdel-Rahman O, Elsayed ZA. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Dig Dis Sci 2013;58:3389-3396. https://doi.org/10.1007/s10620-013-2872-x
  86. van Lienden KP, van den Esschert JW, de Graaf W, Bipat S, Lameris JS, van Gulik TM, et al. Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol 2013;36:25-34. https://doi.org/10.1007/s00270-012-0440-y
  87. O'Neill S, Leuschner S, McNally SJ, Garden OJ, Wigmore SJ, Harrison EM. Meta‐analysis of ischaemic preconditioning for liver resections. Br J Surg 2013;100:1689-1700. https://doi.org/10.1002/bjs.9277
  88. Sanjay P, Watt DG, Wigmore SJ. Systematic review and meta-analysis of haemostatic and biliostatic efficacy of fibrin sealants in elective liver surgery. J Gastrointest Surg 2013;17:829-836. https://doi.org/10.1007/s11605-012-2055-7
  89. Ding H, Yuan JQ, Zhou JH, Zheng XY, Ye P, Mao C, et al. Systematic review and meta-analysis of application of fibrin sealant after liver resection. Curr Med Res Opin 2013;29:387-394. https://doi.org/10.1185/03007995.2013.768216
  90. Simillis C, Li T, Vaughan J, Becker LA, Davidson BR, Gurusamy KS. Methods to decrease blood loss during liver resection: a network meta‐analysis. Cochrane Database Syst Rev 2014;4:CD010683.
  91. Duffy A, Wilkerson J, Greten TF. Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. Hepatology 2013;57:1068-1077. https://doi.org/10.1002/hep.26120
  92. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013;144:323-332. https://doi.org/10.1053/j.gastro.2012.10.005
  93. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013;108:881-891. https://doi.org/10.1038/ajg.2013.5
  94. Huang TS, Shyu YC, Chen HY, Yuan SS, Shih JN, Chen PJ. A systematic review and meta‐analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis‐related hepatocellular carcinoma. J Viral Hepat 2013;20:729-743. https://doi.org/10.1111/jvh.12096
  95. Wang J, He XD, Yao N, Liang WJ, Zhang YC. A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. Can J Gastroenterol 2013;27:351-363.
  96. Li H, Wei Y, Li B. Preoperative steroid administration in liver resection: a systematic review and meta-analysis. Hepatogastroenterology 2013;60:160-169.
  97. Orci LA, Toso C, Mentha G, Morel P, Majno PE. Systematic review and meta-analysis of the effect of perioperative steroids on ischaemia-reperfusion injury and surgical stress response in patients undergoing liver resection. Br J Surg 2013;100:600-609. https://doi.org/10.1002/bjs.9035
  98. Mpabanzi L, van Mierlo KM, Malago M, Dejong CH, Lytras D, Olde Damink SW. Surrogate endpoints in liver surgery related trials: a systematic review of the literature. HPB (Oxford) 2013;15:327-336. https://doi.org/10.1111/j.1477-2574.2012.00590.x
  99. Ren W, Qi X, Yang Z, Han G, Fan D. Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review. Eur J Gastroenterol Hepatol 2013;25:830-841. https://doi.org/10.1097/MEG.0b013e32835eb8d4
  100. Gurusamy KS, Tsochatzis E, Toon CD, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus. Cochrane Database Syst Rev 2013;12:CD006803.
  101. Gurusamy KS, Tsochatzis E, Toon CD, Davidson BR, Burroughs AK. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database Syst Rev 2013;12:CD006573.
  102. Gurusamy KS, Nagendran M, Davidson BR. Methods of preventing bacterial sepsis and wound complications after liver transplantation. Cochrane Database Syst Rev 2014;3:CD006660.
  103. Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos (t) ide analogue (s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant 2013;13:353-362. https://doi.org/10.1111/j.1600-6143.2012.04315.x
  104. Rattanasiri S, McDaniel DO, McEvoy M, Anothaisintawee T, Sobhonslidsuk A, Attia J, et al. The association between cytokine gene polymorphisms and graft rejection in liver transplantation: a systematic review and meta-analysis. Transpl Immunol 2013;28:62-70. https://doi.org/10.1016/j.trim.2012.10.003
  105. Lema Zuluaga GL, Serna Agudelo RE, Zuleta Tobón JJ. Preservation solutions for liver transplantation in adults: celsior versus custodiol: a systematic review and meta-analysis with an indirect comparison of randomized trials. Transplant Proc 2013;45:25-32. https://doi.org/10.1016/j.transproceed.2012.02.031

Cited by

  1. Therapeutic Effects of Mesenchymal Stem Cells for Patients with Chronic Liver Diseases: Systematic Review and Meta-analysis vol.30, pp.10, 2014, https://doi.org/10.3346/jkms.2015.30.10.1405
  2. Assessment for Risk of Bias in Systematic Reviews and Meta-Analyses in the Field of Hepatology vol.9, pp.6, 2014, https://doi.org/10.5009/gnl14451
  3. 모바일 앱을 이용한 당뇨환자관리의 효과: 체계적 문헌고찰과 메타분석 vol.15, pp.1, 2015, https://doi.org/10.5392/jkca.2015.15.01.300
  4. Trends of Meta-analysis in Upper Gastrointestinal Diseases vol.15, pp.2, 2014, https://doi.org/10.7704/kjhugr.2015.15.2.80
  5. Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review vol.10, pp.5, 2016, https://doi.org/10.1007/s12072-016-9705-x
  6. The need for histological subclassification of cirrhosis: a systematic review and meta‐analysis vol.36, pp.6, 2014, https://doi.org/10.1111/liv.12923
  7. Transient elastography versus hepatic venous pressure gradient for diagnosing portal hypertension: a systematic review and meta-analysis vol.23, pp.1, 2014, https://doi.org/10.3350/cmh.2016.0059
  8. Renin angiotensin system in liver diseases: Friend or foe? vol.23, pp.19, 2014, https://doi.org/10.3748/wjg.v23.i19.3396
  9. Diagnostic Accuracy of Hepatic Vein Arrival Time Performed with Contrast-Enhanced Ultrasonography for Cirrhosis: A Systematic Review and Meta-Analysis vol.11, pp.1, 2017, https://doi.org/10.5009/gnl16031
  10. Serum levels of angiotensin converting enzyme as a biomarker of liver fibrosis vol.23, pp.48, 2014, https://doi.org/10.3748/wjg.v23.i48.8439
  11. The effects of non-pharmacological interventions for adults with eating disorders : A systematic review and meta-analysis vol.35, pp.5, 2014, https://doi.org/10.14367/kjhep.2018.35.5.35